Vulvodynia

disease
On this page

Summary

Vulvodynia (MONDO:0021722) is a disease and 70 clinical trials. Top therapeutic interventions include amitriptyline, sodium chloride, and apremilast. A subtype of female reproductive system disorder — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

  • Clinical trials: 70

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

FieldValue
Canonical namevulvodynia
Mondo IDMONDO:0021722
MeSHD056650
ICD-10-CMN94.81
ICD-111539507119
SNOMED CT238968009
UMLSC0406670
MedGen96066
Anatomy (UBERON)UBERON:0000997
Is cancer (heuristic)no

Also known as: vulvodynia

Disease family

This is a subtype of female reproductive system disorder. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › reproductive system disorderfemale reproductive system disordervulvodynia

Related subtypes (33): ectopic pregnancy, pelvic inflammatory disease, endosalpingiosis, vaginal disorder, prolapse of female genital organ, Allen-Masters syndrome, fallopian tube disorder, vulvar disease, uterine disorder, gynatresia, Bartholin duct cyst, ovarian disorder, hymen, imperforate, preterm premature rupture of the membranes, mammary-digital-nail syndrome, Asherman syndrome, uterine cervical aplasia and agenesis, longitudinal vaginal septum, transverse vaginal septum, polycystic ovaries-urethral sphincter dysfunction syndrome, granulomatous mastitis, vaginal atresia, mullerian aplasia, vulvovaginal gingival syndrome, isolated partial vaginal agenesis, female infertility, female reproductive system neoplasm, polyp of vulva, vulval varices, menstrual cycle-dependent periodic fever, Bartholin’s gland disease, delayed puberty, self-limited, menstrual disorder

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 70.

Phase distribution (across all retrieved trials)

PhaseTrials
Not specified51
PHASE210
PHASE37
PHASE2/PHASE31
PHASE11

Top trials by phase / activity

NCTPhaseStatusTitle
NCT07260825PHASE2/PHASE3NOT_YET_RECRUITINGUse of Topical Testosterone and Estrogen vs Estrogen Alone in Vulvodynia: a Randomized Controlled Trial
NCT00496184PHASE3COMPLETEDEfficacy Study of Topical Application of Nifedipine Cream to Treat Vulvar Vestibulitis
NCT01304589PHASE3COMPLETEDSavella in Treatment for Provoked Vestibulodynia
NCT01539317PHASE3COMPLETEDTherapy to Prevent Sexual Pain in Breast Cancer Survivors
NCT02393911PHASE3UNKNOWNDysbiosis in Localized Provoked Vulvodynia (LPV)
NCT02773641PHASE3COMPLETEDPlacebo-controlled RCT of Botulinum Toxin A as a Treatment for Provoked Vestibulodynia
NCT02871661PHASE3UNKNOWNPhysical Therapy as Adjuvant Treatment of Vulvodynia: a Randomized Controled Trial
NCT04057755PHASE3COMPLETEDBotulinum Toxin A as a Treatment for Provoked Vestibulodynia
NCT05955313PHASE2RECRUITINGEffectiveness of Low-dose Naltrexone in Patients With Different Types of Vulvodynia
NCT07257029PHASE2RECRUITINGTopical Ketotifen 0.25% for Secondary Vestibulodynia
NCT07391241PHASE2RECRUITINGA Phase 2 Study to Evaluate the Efficacy and Safety of Pudafensine in Vulvodynia (Provoked Vestibulodynia)
NCT00590590PHASE2COMPLETEDSafety and Efficacy of Two Vaginal Products Versus Placebo in Patients With Vaginal Discomfort
NCT00814632PHASE2COMPLETEDCC-10004 For The Treatment Of Vulvodynia
NCT00853229PHASE2TERMINATEDPregabalin for the Treatment of Vulvodynia
NCT00874484PHASE2COMPLETEDEnoxaparin as Treatment for Vulvodynia
NCT01048177PHASE2WITHDRAWNA Trial of Intravesical Therapy for Interstitial Cystitis in Patients With Generalized Vulvodynia
NCT03598777PHASE2TERMINATEDDysport in Vulvodynia Phase II Study
NCT03682601PHASE2TERMINATEDSexual Penetration Pain in Postmenopausal Women: A Topical Botanical Drug Treatment
NCT01996384PHASE1COMPLETEDProvoked, Localized Vulvodynia Treatment With Acupuncture and Lidocaine Pilot Study
NCT01829204Not specifiedRECRUITINGProspective Data Bank Creation to Study Vaginal Conditions
NCT03640624Not specifiedACTIVE_NOT_RECRUITINGMultidisciplinary Treatment of Chronic Vulvar Pain
NCT04711369Not specifiedRECRUITINGLasertherapy for Vulvodynia
NCT05324280Not specifiedRECRUITINGAcupuncture in a Multidisciplinary Approach for Vulvodynia and Chronic Pelvic Pain
NCT05343182Not specifiedRECRUITINGVestibulectomy Surgical Techniques Comparison Study
NCT05597358Not specifiedACTIVE_NOT_RECRUITINGEfficacy of High Intensity Laser for Provoked Vestibulodynia
NCT06337448Not specifiedNOT_YET_RECRUITINGLight Emitting Diode in the Treatment of Vulvodynia
NCT06472765Not specifiedENROLLING_BY_INVITATIONVaginal Ecosystem and Network in the United States Study
NCT06660212Not specifiedRECRUITINGBiomodulation and Rehabilitation Interventions to tarGet Pelvic Health
NCT06840314Not specifiedRECRUITINGVIBRating vs Traditional Therapy for Treatment of ENTry Dyspareunia
NCT06865963Not specifiedRECRUITINGVestibulodynia At High Resolution: Omics Approach to Improve Diagnosis
NCT06981611Not specifiedRECRUITINGVulvodynia Intervention: the Effect of Multimodal Treatment for Provoked Vulvodynia
NCT06999395Not specifiedRECRUITINGDoes a Virtual Program for Pelvic Pain Improve Pain and Sexual Outcomes in Individuals With Provoked Vestibulodynia?
NCT07092332Not specifiedRECRUITINGYoung Vulvodynia: Effect and Efficacy of Multimodal Treatment.
NCT07553715Not specifiedNOT_YET_RECRUITINGEffectiveness of a Four-Session Focal Shock Wave Therapy Protocol in Women With Vulvodynia
NCT00390013Not specifiedTERMINATEDTo Evaluate if the Medication Gabapentin Lessens Vulvar Pain
NCT00501774Not specifiedCOMPLETEDA Search for Helicobacter Pylori in Localized Vulvodynia
NCT00607490Not specifiedCOMPLETEDA Randomized Clinical Trial for Women With Vulvodynia
NCT00751010Not specifiedCOMPLETEDRelationship: Interstitial Cystitis & Vulvodynia-Part 2
NCT00873301Not specifiedCOMPLETEDThe Effectiveness of Vestibulectomy
NCT01295268Not specifiedTERMINATEDStudy of Emu Oil vs. Placebo for Vulvar Pain in Women.

Drugs tested across these trials (top 30)

MoleculeMax phaseTrials referencing
AMITRIPTYLINE43
SODIUM CHLORIDE42
APREMILAST41
DIPHENHYDRAMINE41
KETOTIFEN FUMARATE41
MILNACIPRAN41
TESTOSTERONE41
PUDAFENSINE21
CHEMBL474647201
1R,2S-MILNACIPRAN01